FMR1 and fragile X syndrome: Until recently, one of the most promising drug candidates for the treatment of FXS was group I metabotropic glutamate receptors (mGluR) modulators because mGluRs are regulated by the FMRP and plays important role in the pathophysiology of FXS2.